EM Vivas · Sickle cell crisis
Acute chest syndrome — exchange transfusion thresholds
Clinical viva on acute chest syndrome recognition, antibiotics, and transfusion strategy including HbS targets.
On this page
Study tools
Target exams
ACEMFRCEMABEM
Prompt
A 24-year-old man with known HbSS presents with severe back and chest pain, fever 38.6 °C, SpO2 90% on air, and a new right lower-lobe infiltrate on chest radiograph. Outline your diagnosis, first-hour management with doses, and when you choose simple versus exchange transfusion.
Interpretation
Reveal interpretationShowHide
This is acute chest syndrome (ACS) — a new pulmonary infiltrate plus a respiratory symptom/sign (fever, chest pain, hypoxia) in sickle cell disease; ACS is the leading cause of death in SCD.[2]
First-hour management
- Oxygen targeting saturation greater than 95 per cent; monitoring; 0.9% saline at no more than maintenance once euvolemic.
- Parenteral opioids within 30 minutes of triage, reassess every 15–30 min; meperidine only if it is the sole effective opioid; consider PCA (lower morphine consumption than continuous infusion).[5]
- Antibiotics: intravenous cephalosporin + oral macrolide.
- Incentive spirometry; bronchodilators if wheeze; escalate respiratory support (HFNC/NIV) for hypoxia.
- Panel: FBC, reticulocytes, film, haemolysis markers, G&S, cultures, gas, CXR.
- Simple transfusion (10 mL/kg) when haemoglobin is more than 10 g/L below baseline (may not be required if baseline ≥90 g/L); do not simple-transfuse SCA above 100 g/L.[1]
- Urgent exchange transfusion for rapid progression (saturation below 90 per cent despite oxygen, increasing distress, progressive infiltrates, and/or haemoglobin falling despite simple transfusion). When exchange is performed, AABB usual goals are HbS not more than 30 per cent and haematocrit under 30 per cent. HbS below 30 per cent immediately prior to the next unit is the STOP chronic programme goal.
- Haematology early; HDU/ICU for severe ACS.
Watch for VOC→ACS evolution from chest-wall splinting; this presentation already meets ACS criteria.[2]
References5ShowHide
- [1]Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members JAMA, 2014.PMID 25203083
- [2]Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group N Engl J Med, 2000.PMID 10861320
- [3]Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support Blood Adv, 2020.PMID 31985807
- [4]Biller E, Zhao Y, Berg M, et al. Red blood cell exchange in patients with sickle cell disease-indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB Transfusion, 2018.PMID 30198607
- [5]van Beers EJ, van Tuijn CF, Nieuwkerk PT, et al. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial Am J Hematol, 2007.PMID 17617790